LCG
MYGN icon

Lisanti Capital Growth’s Myriad Genetics MYGN Stock Holding History

Lisanti Capital Growth’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-48,225
Closed -$2.22M – 113
2018
Q3 		$2.22M Buy
+48,225
New +$2.14M 0.77% 61
2017
Q4 		– Sell
-46,150
Closed -$1.67M – 123
2017
Q3 		$1.67M Buy
46,150
+17,360
+60% +$495K 1.05% 44
2017
Q2 		$744K Buy
+28,790
New +$611K 0.5% 88

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lisanti Capital Growth's MYGN Position: Q4 2018 in Review

Lisanti Capital Growth sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 48,225 shares — an estimated $2.22M sold.

Lisanti Capital Growth first reported a position in MYGN in Q2 2017 and held it in 3 quarters. The position peaked at $2.22M in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • Lisanti Capital Growth reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • Lisanti Capital Growth sold 48,225 Myriad Genetics shares in Q4 2018, an estimated $2.22M.
  • Lisanti Capital Growth first reported a position in Myriad Genetics in Q2 2017 and held it in 3 quarters.
  • Lisanti Capital Growth's Myriad Genetics position peaked at $2.22M in Q3 2018.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Lisanti Capital Growth's 13F filing for Q4 2018, filed 8 Feb 2019.